Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16515
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFurness, Sebastian G B-
dc.contributor.authorHare, David L-
dc.contributor.authorKourakis, Angela-
dc.contributor.authorTurnley, AM-
dc.contributor.authorWookey, Peter J-
dc.date.accessioned2017-01-15T23:09:36Z-
dc.date.available2017-01-15T23:09:36Z-
dc.date.issued2016-10-10-
dc.identifier.citationCell Death Discovery 2016; 2: 16062en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16515-
dc.description.abstractWe have discovered that the accumulation of an anti-calcitonin receptor (anti-CTR) antibody conjugated to a fluorophore (mAb2C4:AF568) provides a robust signal for cells undergoing apoptotic programmed cell death (PCD). PCD is an absolute requirement for normal development of metazoan organisms. PCD is a hallmark of common diseases such as cardiovascular disease and tissue rejection in graft versus host pathologies, and chemotherapeutics work by increasing PCD. This robust signal or high fluorescent events were verified by confocal microscopy and flow cytometry in several cell lines and a primary culture in which PCD had been induced. In Jurkat cells, GBM-L2 and MG63 cells, the percentage undergoing PCD that were positive for both mAb2C4:AF568 and annexin V ranged between 70 and >90%. In MG63 cells induced for the preapoptotic cell stress response (PACSR), the normal expression of α-tubulin, a key structural component of the cytoskeleton, and accumulation of mAb2C4:AF568 were mutually exclusive. Our data support a model in which CTR is upregulated during PACSR and recycles to the plasma membrane with apoptosis. In cells committed to apoptosis (α-tubulin negative), there is accumulation of the CTR-ligand mAb2C4:AF568 generating a high fluorescent event. The reagent mAb2C4:AF568 effectively identifies a novel event linked to apoptosis.en_US
dc.titleA novel ligand of calcitonin receptor reveals a potential new sensor that modulates programmed cell deathen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleCell Death Discoveryen_US
dc.identifier.affiliationDrug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Science, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Pharmacology, Monash University, Clayton, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Anatomy and Neuroscience, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.doi10.1038/cddiscovery.2016.62en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-9554-6556-
dc.identifier.orcid0000-0002-3937-1621-
dc.identifier.pubmedid27777788-
dc.type.austinJournal Articleen_US
local.name.researcherHare, David L
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
crisitem.author.deptCardiology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Dec 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.